Compare AstraZeneca plc (AZN) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs BioNTech SE - ADR — how do they compare? AstraZeneca plc trades at $168.29 (market cap $253.13B), while BioNTech SE - ADR trades at $90.7 (market cap $22.86B). The key difference: AstraZeneca plc is far larger — about 11.1× BioNTech SE - ADR's market cap, and AstraZeneca plc pays a 1.92% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| AZN | BNTX | |
|---|---|---|
Market Cap | $253.13B | $22.86B |
Sector | Health | Health |
52-Week High | $209.48 | $119.34 |
52-Week Low | $137.44 | $83.89 |
Enterprise Value | $279.37B | $6.53B |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
